Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135536 | 0.88 | CTSD (0.53) | ROCK2ROCK1CTSDMAPT | |
| SCHEMBL3143988 | 0.85 | GAA (0.49) | ROCK2ROCK1MCHR1KDM4EMAPT | |
| SCHEMBL3133644 | 0.83 | CTSD (0.58) | ROCK2ROCK1CTSDMCHR1MAPT | |
| SCHEMBL3134869 | 0.83 | CTSD (0.54) | ROCK2ROCK1CTSDKDM4EMAPT | |
| SCHEMBL3132150 | 0.80 | CTSD (0.54) | ROCK2ROCK1CTSDFYN | |
| SCHEMBL4345662 | 0.80 | KDM4E (0.62) | CTSDKDM4EMAPTALDH1A1FLT1 | |
| SCHEMBL3143282 | 0.79 | CTSD (0.64) | ROCK2ROCK1CTSDMCHR1KDM4E | |
| SCHEMBL4338344 | 0.77 | CTSD (0.65) | ROCK2ROCK1CTSDMCHR1MAPT | |
| SCHEMBL24524941 | 0.74 | ABL1 (0.63) | KDM4EMAPTFYNALDH1A1 | |
| SCHEMBL29654682 | 0.74 | ABL1 (0.63) | KDM4EMAPTFYNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2119719-A1 | THIAZEPINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | HSD11B1, HSD17B1, HSD3B1 | ROCK2 3843/4885ROCK1 1809/4885CTSD 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.